PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed Price. Currency in IDR
Add to watchlist
At close: 04:13PM WIB
| Previous Close | 1,445.00 |
| Open | 1,455.00 |
| Bid | 1,805.00 x 0 |
| Ask | 1,245.00 x 0 |
| Day's Range | 1,415.00 - 1,465.00 |
| 52 Week Range | 1,375.00 - 2,200.00 |
| Volume | |
| Avg. Volume | 35,451,126 |
| Market Cap | 65.683T |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 22.88 |
| EPS (TTM) | 62.05 |
| Earnings Date | Aug 02, 2024 - Aug 03, 2024 |
| Forward Dividend & Yield | 38.00 (2.68%) |
| Ex-Dividend Date | May 12, 2023 |
| 1y Target Est | 1,659.10 |
Business WireGenexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.